JP2023542218A5 - - Google Patents
Info
- Publication number
- JP2023542218A5 JP2023542218A5 JP2023518426A JP2023518426A JP2023542218A5 JP 2023542218 A5 JP2023542218 A5 JP 2023542218A5 JP 2023518426 A JP2023518426 A JP 2023518426A JP 2023518426 A JP2023518426 A JP 2023518426A JP 2023542218 A5 JP2023542218 A5 JP 2023542218A5
- Authority
- JP
- Japan
- Prior art keywords
- conjugate
- salt
- cancer
- radionuclide
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20306109.8 | 2020-09-28 | ||
| EP20306109.8A EP3973999A1 (en) | 2020-09-28 | 2020-09-28 | Conjugate or its salt comprising a gastrin-releasing peptide receptor antagonist and uses thereof |
| PCT/EP2021/076107 WO2022063850A1 (en) | 2020-09-28 | 2021-09-22 | Conjugate or its salt comprising a gastrin-releasing peptide receptor antagonist and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023542218A JP2023542218A (ja) | 2023-10-05 |
| JP2023542218A5 true JP2023542218A5 (enExample) | 2024-07-09 |
| JP7824281B2 JP7824281B2 (ja) | 2026-03-04 |
Family
ID=74180915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023518426A Active JP7824281B2 (ja) | 2020-09-28 | 2021-09-22 | ガストリン放出ペプチド受容体アンタゴニストを含むコンジュゲートまたはその塩およびそれらの使用 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20230372552A1 (enExample) |
| EP (2) | EP3973999A1 (enExample) |
| JP (1) | JP7824281B2 (enExample) |
| KR (1) | KR20230078690A (enExample) |
| CN (1) | CN116322798A (enExample) |
| AU (1) | AU2021348219A1 (enExample) |
| BR (1) | BR112023003690A2 (enExample) |
| CA (1) | CA3189680A1 (enExample) |
| DK (1) | DK4188457T3 (enExample) |
| ES (1) | ES2989009T3 (enExample) |
| FI (1) | FI4188457T3 (enExample) |
| HR (1) | HRP20241285T1 (enExample) |
| HU (1) | HUE068360T2 (enExample) |
| IL (1) | IL300486A (enExample) |
| LT (1) | LT4188457T (enExample) |
| PL (1) | PL4188457T3 (enExample) |
| PT (1) | PT4188457T (enExample) |
| RS (1) | RS65994B1 (enExample) |
| SI (1) | SI4188457T1 (enExample) |
| SM (1) | SMT202400392T1 (enExample) |
| WO (1) | WO2022063850A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025163082A1 (en) | 2024-01-31 | 2025-08-07 | Molecular Partners Ag | Dll3-specific binding constructs and their use in radiotherapy |
| WO2026150109A1 (en) | 2025-01-10 | 2026-07-16 | Molecular Partners Ag | Mesothelin-specific binding constructs and their use in radiotherapy |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2100900A1 (en) | 2008-03-07 | 2009-09-16 | Universitätsspital Basel | Bombesin analog peptide antagonist conjugates |
| US20150217006A1 (en) * | 2014-02-06 | 2015-08-06 | Immunomedics, Inc. | Al-f-18-labeled, al-f-19-labeled and ga-68-labeled gastrin-releasing peptide receptor (grpr)-antagonists for imaging of prostate cancer |
| CA3050094C (en) | 2017-01-12 | 2024-01-02 | Radiomedix Inc. | Treatment of cancer cells overexpressing somatostatin receptors using ocreotide derivatives chelated to radioisotopes |
-
2020
- 2020-09-28 EP EP20306109.8A patent/EP3973999A1/en not_active Withdrawn
-
2021
- 2021-09-22 HR HRP20241285TT patent/HRP20241285T1/hr unknown
- 2021-09-22 PT PT217785021T patent/PT4188457T/pt unknown
- 2021-09-22 EP EP21778502.1A patent/EP4188457B1/en active Active
- 2021-09-22 ES ES21778502T patent/ES2989009T3/es active Active
- 2021-09-22 HU HUE21778502A patent/HUE068360T2/hu unknown
- 2021-09-22 KR KR1020237011366A patent/KR20230078690A/ko active Pending
- 2021-09-22 FI FIEP21778502.1T patent/FI4188457T3/fi active
- 2021-09-22 US US18/246,706 patent/US20230372552A1/en active Pending
- 2021-09-22 LT LTEPPCT/EP2021/076107T patent/LT4188457T/lt unknown
- 2021-09-22 BR BR112023003690A patent/BR112023003690A2/pt unknown
- 2021-09-22 RS RS20241053A patent/RS65994B1/sr unknown
- 2021-09-22 AU AU2021348219A patent/AU2021348219A1/en active Pending
- 2021-09-22 CA CA3189680A patent/CA3189680A1/en active Pending
- 2021-09-22 SM SM20240392T patent/SMT202400392T1/it unknown
- 2021-09-22 DK DK21778502.1T patent/DK4188457T3/da active
- 2021-09-22 JP JP2023518426A patent/JP7824281B2/ja active Active
- 2021-09-22 WO PCT/EP2021/076107 patent/WO2022063850A1/en not_active Ceased
- 2021-09-22 SI SI202130186T patent/SI4188457T1/sl unknown
- 2021-09-22 IL IL300486A patent/IL300486A/en unknown
- 2021-09-22 PL PL21778502.1T patent/PL4188457T3/pl unknown
- 2021-09-22 CN CN202180065166.XA patent/CN116322798A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230122957A1 (en) | Psma ligands for imaging and endoradiotherapy | |
| TWI657827B (zh) | 用於正子斷層掃描之化合物 | |
| US12214059B2 (en) | Cleavable radioligands for targeting cell surface receptors and uses thereof | |
| ES2615805T3 (es) | Conjugados de antagonista de péptido análogo de la bombesina | |
| CN104837819B9 (zh) | 神经降压肽受体配体 | |
| CN112074526B (zh) | 作为治疗性放射性药物的177Lu-DOTA-HYNIC-iPSMA | |
| US20140039153A1 (en) | Cancer imaging and treatment | |
| Bolzati et al. | Chelating systems for 99mTc/188Re in the development of radiolabeled peptide pharmaceuticals | |
| US20220218852A1 (en) | Novel radiolabelled cxcr4-targeting compounds for diagnosis and therapy | |
| JP2008266342A (ja) | 部位特異的ターゲッティング用の放射性標識ペプチド組成物 | |
| US11639373B2 (en) | Therapeutic and diagnostic agents for cancer | |
| US20250288704A1 (en) | Cxcr4-ligands for diagnostic and therapeutic use and precursors thereof | |
| WO2025246177A1 (zh) | 一种靶向fap的二聚化合物及其探针和应用 | |
| CN103547291B (zh) | 锝标记的肽 | |
| WO2015119763A1 (en) | Al-f-18-labeled, al-f-19-labeled and ga-68-labeled gastrin-releasing peptide receptor (grpr)-antagonists for imaging of prostate cancer | |
| FI4188457T3 (fi) | Gastriinia vapauttavan peptidin reseptorin antagonistia käsittävä konjugaatti tai sen suola ja sen käyttötapoja | |
| US9365599B2 (en) | N3S1 chelator-folate derivatives, preparation method thereof and composition for diagnosis or treatment of cancer containing the same as an active ingredient | |
| TW202327665A (zh) | 基於肽的新型診斷劑和治療劑 | |
| Waibel et al. | Radiopharmaceuticals for targeted tumor diagnosis and therapy | |
| JP2023536261A (ja) | Ｃｃｋｂ受容体陽性腫瘍または癌の画像化方法におけるガリウム標識ガストリン類似体および使用 | |
| KR101551232B1 (ko) | Ｎ3ｓ1형의 새로운 킬레이터가 접합된 폴레이트 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암 진단 또는 치료용 조성물 | |
| CN113350531A (zh) | 前列腺特异性膜抗原结合配体偶联物及其应用 | |
| US20250360237A1 (en) | Targeting system for cancer treatment | |
| HK40111230A (en) | Cleavable radioligands for targeting cell surface receptors and uses thereof | |
| CN118019749A (zh) | 制备18f标记的甲硅烷基氟化化合物的方法 |